https://www.matissepharmaceuticals.com/ 2026-04-03 daily 1 https://www.matissepharmaceuticals.com/404 2023-05-08 weekly 0.7 https://www.matissepharmaceuticals.com/thank-you-for-your-subscription 2023-05-08 weekly 0.7 https://www.matissepharmaceuticals.com/cookie-statement 2023-05-24 weekly 0.7 https://www.matissepharmaceuticals.com/about-us 2023-05-04 weekly 0.7 https://www.matissepharmaceuticals.com/about-us/who-we-are 2025-12-11 monthly 0.6 https://www.matissepharmaceuticals.com/about-us/mission-vision-and-values 2023-05-04 monthly 0.6 https://www.matissepharmaceuticals.com/about-us/management-board 2023-05-04 monthly 0.6 https://www.matissepharmaceuticals.com/about-us/supervisory-board 2023-05-04 monthly 0.6 https://www.matissepharmaceuticals.com/about-us/scientific-advisory-board 2023-05-04 monthly 0.6 https://www.matissepharmaceuticals.com/about-us/partnering 2025-12-11 monthly 0.6 https://www.matissepharmaceuticals.com/about-us/code-of-conduct 2023-05-04 monthly 0.6 https://www.matissepharmaceuticals.com/our-technology 2023-05-04 weekly 0.7 https://www.matissepharmaceuticals.com/our-technology/what-we-are-targeting 2025-12-11 monthly 0.6 https://www.matissepharmaceuticals.com/our-technology/mechanism-of-action 2025-09-25 monthly 0.6 https://www.matissepharmaceuticals.com/our-technology/isupartob-sodium 2025-12-11 monthly 0.6 https://www.matissepharmaceuticals.com/pipeline 2025-12-11 weekly 0.7 https://www.matissepharmaceuticals.com/pipeline/pipeline 2025-09-29 monthly 0.6 https://www.matissepharmaceuticals.com/pipeline/clinical-trials 2025-12-11 monthly 0.6 https://www.matissepharmaceuticals.com/pipeline/ip-position 2025-12-11 monthly 0.6 https://www.matissepharmaceuticals.com/sepsis-and-septic-shock 2023-05-04 weekly 0.7 https://www.matissepharmaceuticals.com/sepsis-and-septic-shock/what-is-sepsis 2025-09-25 monthly 0.6 https://www.matissepharmaceuticals.com/sepsis-and-septic-shock/current-treatment 2023-05-17 monthly 0.6 https://www.matissepharmaceuticals.com/sepsis-and-septic-shock/health-impact 2023-05-15 monthly 0.6 https://www.matissepharmaceuticals.com/sepsis-and-septic-shock/economic-impact 2025-09-25 monthly 0.6 https://www.matissepharmaceuticals.com/news 2023-05-04 weekly 0.7 https://www.matissepharmaceuticals.com/contact 2023-05-04 weekly 0.7 https://www.matissepharmaceuticals.com/careers 2023-05-04 weekly 0.7 https://www.matissepharmaceuticals.com/thank-you 2023-05-08 weekly 0.7 https://www.matissepharmaceuticals.com/privacy-policy 2023-05-17 weekly 0.7 https://www.matissepharmaceuticals.com/news/matisse-pharmaceuticals-appoints-marcel-jacobs-as-ceo 2024-01-02 weekly 0.7 https://www.matissepharmaceuticals.com/news/matisse-pharmaceuticals-closes-eur-36-million-financing-round 2024-01-04 weekly 0.7 https://www.matissepharmaceuticals.com/news/matisse-pharmaceuticals-strengthens-scientific-advisory-board-with-prof-john-marshall-and-prof-mervyn-singer 2023-05-23 weekly 0.7 https://www.matissepharmaceuticals.com/news/approval-from-the-dutch-health-authorities-to-initiate-a-phase-i-study-with-matisse-pharmaceuticals-lead-compound-m6229-in-sepsis 2023-05-22 weekly 0.7 https://www.matissepharmaceuticals.com/news/matisse-pharmaceuticals-raises-financing-for-its-phase-iiia-clinical-trial-treating-patients-suffering-from-sepsis 2023-05-31 weekly 0.7 https://www.matissepharmaceuticals.com/news/matisse-pharmaceuticals-about-to-start-third-dose-level-in-a-phase-iiia-study-with-its-lead-compound-m6229-in-septic-patients 2023-05-30 weekly 0.7 https://www.matissepharmaceuticals.com/news/matisse-pharmaceuticals-appoints-kees-groen-and-marcel-jacobs-to-board-of-directors-and-management-board 2023-05-30 weekly 0.7 https://www.matissepharmaceuticals.com/news/matisse-pharmaceuticals-meets-primary-objectives-in-study-with-m6229-in-critically-ill-sepsis-patients 2024-01-30 weekly 0.7 https://www.matissepharmaceuticals.com/news/matisse-pharmaceuticals-appoints-prof-carolyn-calfee-to-the-scientific-board 2024-10-22 weekly 0.7 https://www.matissepharmaceuticals.com/news/matisse-pharmaceuticals-receives-bfarm-approval-to-study-a-prolonged-infusion-of-m6229 2024-10-24 weekly 0.7 https://www.matissepharmaceuticals.com/news/matisse-pharmaceuticals--epidisease-receive-eu-funding-for-their-ehistocure-project 2025-06-26 weekly 0.7 https://www.matissepharmaceuticals.com/news/matisse-pharmaceuticals-successfully-completes-study-with-prolonged-infusion-of-m6229-in-healthy-volunteers 2025-11-13 weekly 0.7 https://www.matissepharmaceuticals.com/news/matisse-pharmaceuticals-receives-inn-isupartob-sodium-recognizing-firstinclass-drug-status-for-m6229 2025-12-11 weekly 0.7